Monopar Therapeutics Inc. (NasdaqCM: MNPR)
Health Care · Biotechnology · US
$77.05
-2.42% today · -22.6% 1Y
Monopar Therapeutics Inc. (NasdaqCM: MNPR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $529.99M and employs 22 people.
Over the last twelve months the share price has lost 22.6%, trading between 50.07 and 124.82.
Tweenvest scores Monopar Therapeutics Inc. across four factors: quality 68/100, value 74/100. Its strongest factor is value.
MNPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $529.99M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.18
- Dividend yield
- —
- Beta (5Y)
- 1.51
- 52-week high
- $124.82
- 52-week low
- $50.07
- Avg volume (3M)
- —
- Shares outstanding
- 6.71M
- Employees
- 22
- Next earnings
- —
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- ISIN
- US61023L2079
- Founded
- 2014
- Listed since
- Dec 19, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $541.29M | HK$10.43 | -2.71% |
| Valneva SEENXTPA: VLA | $537.87M | €2.53 | +0.08% |
| Bright Minds Biosciences Inc.CNSX: DRUG | $533.01M | CA$77.10 | +9.22% |
| Puma Biotechnology, Inc.NasdaqGS: PBYI | $531.17M | $10.29 | 0.00% |
| CytomX Therapeutics, Inc.NasdaqGS: CTMX | $527.32M | $2.42 | -5.84% |
| TaiMed Biologics Inc.TPEX: 4147 | $522.91M | NT$61.20 | -0.33% |
| Qingdao Vland Biotech INC.SHSE: 603739 | $522.82M | CN¥13.84 | -1.42% |
| Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683 | $516.50M | CN¥26.43 | +3.48% |
Figures last refreshed Oct 11, 2026.